Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Baseline and Post-Bortezomib gene expression profiling of CD138 purified bone marrow plasma cells from multiple myeloma patients

ABSTRACT: High PSMD4 expression levels in plasma cells are linked to poor prognosis in multiple myeloma. Additional file available-E-TABM-1138.additional.zip

ORGANISM(S): Homo sapiens

SUBMITTER: Pingping Qu

PROVIDER: E-TABM-1138 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

Shaughnessy John D JD Qu Pingping P Usmani Saad S Heuck Christoph J CJ Zhang Qing Q Zhou Yiming Y Tian Erming E Hanamura Ichiro I van Rhee Frits F Anaissie Elias E Epstein Joshua J Nair Bijay B Stephens Owen O Williams Ryan R Waheed Sarah S Alsayed Yazan Y Crowley John J Barlogie Bart B

Blood 20110531 13

Gene expression profiling (GEP) of purified plasma cells 48 hours after thalidomide and dexamethasone test doses showed these agents' mechanisms of action and provided prognostic information for untreated myeloma patients on Total Therapy 2 (TT2). Bortezomib was added in Total Therapy 3 (TT3), and 48 hours after bortezomib GEP analysis identified 80 highly survival-discriminatory genes in a training set of 142 TT3A patients that were validated in 128 patients receiving TT3B. The 80-gene GEP mode ...[more]

PMID: 21628408

Similar Datasets

Transcription profiling by array of human CD138 purified bone marrow plasma cells, CD27 memory B-cells, polyclonal plasmablastic cells and human myeloma cell lines

Project description:Gene expression profiling of CD138 purified bone marrow plasma cells of healthy donors, CD27 memory B-cells, cultured ployclonal plasmablastic cells and cultured human myeloma cell lines. Samples from healthy donors have been re-used from ArrayExpress experiment E-MEXP-2360. Some of the myeloma cell line samples have been re-used from E-TABM-937 and E-TABM-1088.

2017-02-23 | E-MTAB-5212 | biostudies-arrayexpress

Group B meningococcus (MC58) - Wild type and delta hfq strains grown at mid log in GC broth

Project description:Analysis of global transcription profile of wild type MC58 and hfq deletion mutant strains grown in GC until mid log phase. Original file with experiment results is in the archive E-TABM-1111.additional.zip.

2011-12-31 | E-TABM-1111 | biostudies-arrayexpress

Gene Expression Changes in Myeloma Cells Following Short Term In-vivo Pomalidomide (Pom) or Bortezomib (Bor) Exposure

Project description:For Pom pharmacogenomic study, gene expression profiling (GEP) analyses were performed on samples from 18 patients, all of whom had received prior treatment with Len and Bor. CD138-purified plasma cells were collected from patients prior to and 48 hours after the first dose of Pom (4.0 mg/d for 2 days) and samples were hybridized to Affymetrix U133Plus2.0 arrays according to the manufacturer's recommendations. For Bor study, GEP analyses were performed on samples from 25 previously treated patients on Total Therapy 6 (TT6) trial using Affymetrix U133Plus2.0 arrays. Samples were collected prior to and 48 hours post a test dose Bor (1.0mg/m2).

2015-01-31 | E-MTAB-2441 | biostudies-arrayexpress

Transcriptiion profiling by array of human ratiometric mixes of high quality RNA from different tissues using different labeling protocols to provide a mechanism for assessing process improvement

Project description:Ratiometric controls were prepared from commercial sources of high quality RNA from human tissues with distinctly different expression patterns. The samples were processed using six different target labeling protocols and replicate datasets were generated on high density gene expression microarrays. The area under the curve from receiver operating characteristic plots was calculated as a measure of diagnostic performance. The reliable region of the dynamic range was derived from log ratio deviation plots made for each dataset. These samples and metrics provide a mechanism for assessing process improvement that can be used by clinical laboratories conducting microarray assays. <br><br>Additional processed data files are available on the FTP site for this experiment in E-TABM-1091.additional.zip.

2011-04-08 | E-TABM-1091 | biostudies-arrayexpress

Expression data of HGF/cMET pathway in prostate cancer DU145 cell line

Project description:DU145 prostate cancer cells were treated with 25 ng/ml hepatocyte growth factor (HGF) or vehicle for 2, 8, or 24 hours. HGF stimulates the cMET protein, a tyrosine kinase transmembrane protein. The aim of this study is to determine the role of the HGF/cMET pathway in immature cells of established prostate cancer. HGF stimulation of DU145 prostate cancer cell line led to cell migration in culture, formation of sprouts in Matrigel and inhibition of growth. These biological effects went together with induction of a stem-like phenotype as defined by up-regulation of CD49b, CD49f, CD44 and SOX9, and down-regulation of CD24 on gene-expression arrays and quantitative PCR. The shift towards a stem-like phenotype was reflected by protein modifications on FACS, Western blot, and enhanced rapid adhesion to collagen I. Small molecules SU11274 and PHA665752 were able to inhibit both morphologic and molecular HGF effects. DU145 cells were stimulated for 2, 8 and 24 hours with 25 ng/ml HGF or vehicle. For each time point two arrays analyses were performed. One for cells stimulated with a vehicle and one for the HGF stimulated cells. Six arrays were performed in total in this study.

2011-12-16 | E-GEOD-16659 | biostudies-arrayexpress

Dosage Suppression Genetic Interaction Networks

Project description:A functionally diverse subset of yeast temperatures sensitive deletion mutants were transformed with a pool of barcoded yeast ORFs to identify dosage suppressors. Objective: To assess the relative strain proportion after growing DNA barcoded yeast deletion strains in a mixed pools. The barcodes are amplified from the mixed population, and the intensity of each labelled barcodes on the Tag4 array indicate the relative contribution of that strain to the mixed pool. Note: File MoBY_strains.txt available in E-TABM-1147.additional.zip

2012-04-21 | E-TABM-1147 | biostudies-arrayexpress

Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma cells [GEP data]

Project description:Copy number and Gene expression profiling of HT-29 wild-type and bortezomib resistant cell lines Identification of mechanisms of bortezomib resistance Gene expression differences between HT-29 cell line variants

2011-06-04 | E-GEOD-29712 | biostudies-arrayexpress

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.

Project description:Protein analysis in bone marrow samples from patients with multiple myeloma has been limited by the low concentration of proteins obtained after CD138+ cell selection. A novel approach based on capillary nano-immunoassay could make it possible to quantify dozens of proteins from each myeloma sample in an automated manner. Here we present a method for the accurate and robust quantification of the expression of multiple proteins extracted from CD138-purified multiple myeloma samples frozen in RLT Plus buffer, which is commonly used for nucleic acid preservation and isolation. Additionally, the biological and clinical value of this analysis for a panel of 12 proteins essential to the pathogenesis of multiple myeloma was evaluated in 63 patients with newly diagnosed multiple myeloma. The analysis of the prognostic impact of CRBN/Cereblon and IKZF1/Ikaros mRNA/protein showed that only the protein levels were able to predict progression-free survival of patients; mRNA levels were not associated with prognosis. Interestingly, high levels of Cereblon and Ikaros proteins were associated with longer progression-free survival only in patients who received immunomodulatory drugs and not in those treated with other drugs. In conclusion, the capillary nano-immunoassay platform provides a novel opportunity for automated quantification of the expression of more than 20 proteins in CD138+ primary multiple myeloma samples.

| S-EPMC5927993 | biostudies-literature

Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma.

Project description:Although recent advances have substantially improved the management of multiple myeloma, it remains an incurable malignancy. We now demonstrate that anti-CD138 molecules genetically fused to type I interferons (IFN) synergize with the approved therapeutic bortezomib in arresting the proliferation of human multiple myeloma cell lines both in vitro and in vivo. The anti-CD138-IFNα14 fusion protein was active in inducing increased expression of signal transducer and activator of transcription 1 (STAT1) and its phosphorylation while the cell death pathway induced by bortezomib included generation of reactive oxygen species. Interferon regulatory factor 4 (IRF4), an important survival factor for myeloma cells, was down regulated following combination treatment. Induction of cell death appeared to be caspase-independent because treatment with inhibitors of caspase activation did not decrease the level of cell death. The observed caspase-independent synergistic cell death involved mitochondrial membrane depolarization, and poly(ADP-ribose) polymerase-1 (PARP-1) cleavage, and resulted in enhanced induction of apoptosis. Importantly, using 2 different in vivo xenograft models, we found that combination therapy of anti-CD138-IFNα14 and bortezomib was able to cure animals with established tumors (7 of 8 using OCI-My5 or 8 of 8 using NCI-H929). Thus, the combination of anti-CD138-IFNα with bortezomib shows great promise as a novel therapeutic approach for the treatment of multiple myeloma, a malignancy for which there are currently no cures.

| S-EPMC5058616 | biostudies-literature

Expression data from human lymphoma endothelium and reactive lymph node-derived endothelium

Project description:Angiogenesis plays a key role in tumor metastasis. Many genes may act in this process including formation of vessels, immune evasion,etc. Different gene expression profiles between lymphoma endothelium cells and reactive lymph node-derived endothelium cells may uncover these genes. And intensive mechanism researches on such key genes may explain the mechanisim of tumor-specific angiogenesis and help to explore effective treatment strategies to prevent/reverse tumor metastasis. We use microarrays to detail gene expression profiles of human lymphoma endothelium and reactive lymph node-derived endothelium. Lymph nodes were taken from surgery samples of cases pathologically diagnosed DLBCL (diffuse large B-cell lymphoma), PTL (peripheral T cell lymphoma) and reactive lymph nodes. The pure endothelium cells were isolated by LCM after immunohistochemical staining of CD34. We found Tim-3 was preferentially expressed on lymphoma-derived ECs via different expression profiles between lymphoma ECs and reactive lymph node-derived ECs. Intensive researches were carried out on Tim-3-expressing -ECs and we found that Tim-3 -expressing-Ecs may play important role on EC-mediated tumor evasion.

2010-01-14 | E-GEOD-19882 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data